#United States #medical technology #Fiscal 2025 #Franklin Lakes #Becton Dickinson

BD Reports Third Quarter Fiscal 2025 Financial Results

On August 7, 2025, BD (Becton, Dickinson and Company) disclosed its fiscal year 2025 third quarter financial results, showcasing a remarkable performance with total revenue reaching $5.5 billion. This figure marks a solid 10.4% increase compared to the same quarter from the previous year, with an 8.5% adjustment for foreign exchange fluctuations and a 3.0% organic growth. Notably, the adjusted diluted earnings per share (EPS) also experienced significant growth, rising to $3.68, a 5.1% increase year-over-year.

Tom Polen, the chairman, CEO, and president of BD, expressed that the company's organic growth trajectory has strengthened during this quarter, driven by their BD Excellence initiative which has positively impacted margins and EPS. He emphasized the company’s confidence to raise its full-year adjusted diluted EPS guidance to a range of $14.30 to $14.45, reflecting an increase and reaffirming organic revenue growth expectations for the year.

Key Financial Highlights

• - Total Revenue: $5,509 million (Q3 2025) vs. $4,990 million (Q3 2024)
• - Adjusted Revenue: $5,509 million (2025) compared to $5,057 million (2024)
• - GAAP Diluted EPS: $2.00 in 2025 compared to $1.68 in 2024
• - Adjusted Diluted EPS: $3.68, up from $3.50 year-over-year

The overall gross margin also saw improvements, with both GAAP and adjusted margins increasing by 160 and 50 basis points, respectively. Operating income surged by 46.6% with GAAP figures reflecting this positive trend.

Future Outlook and Strategic Moves

Looking ahead, BD remains committed to maintaining its growth momentum, with expectations to complete the remaining $250 million of its $1 billion share buyback commitment by the conclusion of the fiscal year 2025. BD also announced a strategic agreement to merge its Biosciences and Diagnostic Solutions business with Waters Corporation, aiming to forge a leading life sciences and diagnostics entity focusing on high-volume testing, anticipating a favorable financial outlook.

Recent Strategic Developments

• - Investment in Production: BD's efforts to enhance its manufacturing capabilities led to a planned investment of $35 million in a facility in Nebraska to bolster the production of its BD® PosiFlush™ Prefilled Flush Syringe.
• - FDA Approvals and Advances: The company recently submitted an application to the FDA for the BD Onclarity™ HPV Assay, showcasing its commitment to expanding its diagnostic portfolio. It also achieved FDA clearance for a rapid COVID-19 testing system, indicating responsiveness to public health needs.

Performance by Segments

In examining performance across segments:

• - BD Medical: Experienced significant growth, particularly within the Medication Delivery Solutions business which reported a 14.4% increase in revenue.
• - BD Life Sciences: Saw a slight decline of 0.5%, reflecting challenging conditions in the diagnostics market.
• - BD Interventional: Registered a 7.2% growth, buoyed by robust advancements in Urology and Critical Care sectors.

Conclusion

BD is effectively capitalizing on its strengths and addressing challenges within its markets. With a clear focus on innovation, strategic partnerships, and operational excellence, the company is positioning itself for long-term success and sustained growth in the evolving medical technology landscape. The favorable results reflect BD's dedication to enhancing healthcare delivery and its robust business strategies aimed at driving shareholder value.

To learn more about BD and its latest financial performance, visit BD's Investor Relations page for their upcoming earnings call and additional insights.